CVS Health Corporation (NYSE:CVS) stands poised for growth, supported by its comprehensive range of insured and self-insured medical, pharmacy, dental, and behavioral health products and services. The recent acquisition of Oak Street Health further enhances its consumer care delivery strategy, indicating potential for future growth.

However, it’s crucial to note the challenges posed by intense competition and challenging macroeconomic conditions. Over the past year, CVS stock has experienced a 30.3% decline, in contrast to the industry’s 35.1% fall and the S&P 500’s 12.2% rise.

Let’s delve deeper into the factors influencing CVS’s outlook.

Positive Factors

1. Health Care Benefit Potential: CVS Health has made significant strides with the introduction of its Health Care Benefits business arm following the acquisition of health insurance giant Aetna. The third quarter of 2023 saw a growth in medical membership to 25.7 million, reflecting progress across various product lines, including individual exchange, Medicare, and commercial. The company’s leadership in zero-dollar premium products positions it well, with approximately 84% of Medicare eligibles expected to have access to Aetna plans in this category in 2024.

2. Health Services Business Momentum: CVS Health continues to gain momentum in its Health Services segment, driven by pharmacy claims growth, specialty pharmacy, and brand inflation. Both Signify Health and Oak Street Health, operating within the Health Services segment, have demonstrated strong business performance. As Oak Street expands its presence, opportunities for higher patient growth are anticipated to increase.

3. Strong Solvency and Returns to Investors: CVS Health maintains a robust financial position, ending the third quarter of 2023 with $16.19 billion in cash and cash equivalents. Despite total year-end debt being higher than the corresponding cash level, the near-term payable debt is lower than the short-term cash level, indicating positive solvency. This is particularly reassuring during economic downturns, ensuring the company has sufficient cash for debt repayment.

Challenges

1. Competitive Landscape: Despite significant client wins, CVS Health faces intense competition and challenging industry conditions, with competitors such as Walgreens, Target, and Wal-Mart expanding their pharmacy businesses.

2. International Market Risks: CVS Health’s international operations expose the company to various risks, including political, legal, compliance, operational, regulatory, economic, and other uncertainties. These risks vary across countries and encompass regional and geopolitical conditions, government intervention, and pricing constraints.

Estimate Trends

In the past 90 days, the  Consensus Estimate for CVS Health’s fiscal 2023 earnings has slightly decreased from $8.62 to $8.59 per share. However, the Consensus Estimate for fiscal 2023 revenues is projected at $352.9 billion, indicating a 9.5% rise from the year-ago reported number.

Key Alternatives

For investors seeking alternatives in the broader medical space, consider Abbott Laboratories (NYSE:ABT), DexCom, Inc. (NASDAQ:DXCM), and Integer Holdings Corporation (NYSE:ITGR).

Abbott outperformed expectations in third-quarter 2023, posting adjusted earnings per share (EPS) of $1.14 and revenues of $10.14 billion.

DexCom reported third-quarter 2023 adjusted EPS of 50 cents, surpassing estimates by 47.1%, with revenues reaching $975 million.

Integer Holdings exceeded estimates in third-quarter 2023 with adjusted EPS of $1.27 and revenues of $404.7 million.

These alternatives present potential investment opportunities with favorable growth prospects.

Featured Image-  Megapixl @Jetcityimage

Please See Disclaimer